Latest news with #UniversityOfRochester
Yahoo
24-05-2025
- Yahoo
Police presence near Eastman School of Music shuts down surrounding streets
ROCHESTER, N.Y. (WROC) — Rochester Police and University of Rochester Public Safety vehicles line the perimeter of the Eastman School of Music Friday. A News 8 photojournalist on scene said police have been seen interviewing bystanders, and the intersection of Swan Street and East Main Street has been blocked off with caution tape by police. A cop was seen walking arm in arm with a man into the building, who was then shortly walked back outside and placed in the back of a cop car. No handcuffs were visible. An undamaged car is being towed from the area, according to our photojournalist. News 8 has reached out to RPD for more information. Stay with RochesterFirst as this scene develops. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
News.com.au
15-05-2025
- Health
- News.com.au
Doctors warn popular drink may increase risk of blood cancer
A new study has revealed that a 'common' ingredient found in a string of popular energy drinks could elevate the risk of blood cancers. US researchers have found that taurine, an amino acid often added to energy drinks such as Red Bull and Celsius, can act as a fuel source for leukaemia cancer cells, which develop in bone marrow. The study authors have since warned consumers to exercise caution when consuming drinks containing the metabolism boosting ingredient, which are sold at supermarkets around the world. 'Since taurine is a common ingredient in energy drinks... our work suggests that it may be of interest to carefully consider the [risks and] benefits of supplemental taurine in leukaemia patients,' the study, published in Nature, claims. While the body naturally produces taurine, it has been used to alleviate chemotherapy side effects in leukaemia patients. But researchers at the University of Rochester in New York believe that additional intake might actually worsen the blood cancer. They said that their study highlights the need to carefully evaluate the risks and benefits of extra taurine for leukaemia patients as well as the risk to those who drink energy drinks, given how readily available the product is. Although the study is still in its initial phases, the researchers are optimistic that targeting taurine production in leukaemia cells could represent a new approach for treating these aggressive diseases. Their experiments on mice and human leukaemia cells showed that blocking taurine from entering cells could slow disease progression. The study is part of broader research that is looking into taurine's potential role in fuelling other cancers, such as colorectal cancer. According to Mayo Clinic, taurine occurs naturally in foods with protein, such as meat or fish. It is often used in energy drinks as it can help with digestion, maintain proper hydration and electrolyte balances and support the general function of your central nervous system. The new study investigated mice with the SLC6A6 gene, which is responsible for taurine transportation throughout the body. Researchers also transplanted samples of human leukaemia cells into these mice. They found that a specific group of healthy bone marrow cells produces taurine, the environment where leukaemia develops. The SLC6A6 gene then carries this taurine from the bone marrow to the leukaemia cells. As the cancer cells feed on taurine, they go through a process called glycolysis, which is where cells break down glucose to make energy. This process gives cancer cells the energy to divide and multiply, which is why it can make leukaemia more aggressive, as it makes more cancer cells form. According to Cancer Australia, 5202 new cases of leukaemia were diagnosed in Australia in 2022. Approximately 2121 people died from the disease in the same year. Currently, 135,000 people are living with blood cancer or a related blood disorder in Australia today.
Yahoo
15-05-2025
- Business
- Yahoo
Genflow Biosciences PLC Announces Key SIRT6 Patent Application
LONDON, UNITED KINGDOM / / May 15, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, announces that the Japanese Patent Office has advanced its SIRT6-related patent application (Application No. JP 2024515284) to the national examination phase. The application, titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," was originally filed on 13 May 2022 and is jointly owned by the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine. Genflow holds the exclusive license to this intellectual property. The invention covers novel SIRT6 gene variants that play a central role in genomic stability, metabolic regulation, and healthy aging. These variants underpin Genflow's core therapeutic platform and represent a key part of its pipeline targeting age-related diseases. The progression to national examination in Japan marks an important step in Genflow's strategy to establish broad international patent protection. Japan, with one of the world's most rapidly aging populations, is a priority market for longevity-related innovation. Dr. Eric Leire, CEO of Genflow Biosciences, commented: "We are pleased to see continued momentum in the protection of our SIRT6 intellectual property. Japan represents a strategically important jurisdiction for Genflow, and advancing this patent application strengthens our global positioning as a leader in longevity gene therapy." Genflow continues to progress its preclinical and clinical programs targeting age-related pathologies using the SIRT6 gene variants. Contacts Genflow Biosciences Harbor Access Dr Eric Leire, CEO Jonathan Paterson, Investor Relations +32-477-495-881 +1 475 477 9401 Corporate Brokers Capital Plus Partners Ltd Jon Critchley, +44 0203 821 6168 About Genflow Biosciences Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Expected to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit and follow the Company on LinkedIn and Twitter/X. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
